Decera Clinical Education Oncology Podcast

In this podcast episode, Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, discuss ADCs for HER2-negative/ultralow/low metastatic breast cancer, including: Classifying HER2 expression in MBC today (HER2 negative/ultralow/low/positive) and why this is important ADCs for HER2-negative/ultralow/low MBC Patient communication: best practices in discussing treatment goals and potential AEs Presenters: Aditya Bardia, MD, MPH, FASCO Professor of Medicine Geffen School of Medicine University of California Los Angeles, California Ruta Rao, MD​ Medical Director, Rush University Cancer Center Professor of Medicine Rush University Medical Center Chicago, Illinois ​ Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc. Link to full program: https://bit.ly/47JLtBt Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advanced practice providers discuss biomarker testing in patients with colorectal cancer. Listen in to learn from Ann Marie Siney, RN, MSN, ANP-BC, and Kathleen Boyle, DScPAS, PA-C, about familial cancer syndromes associated with colorectal cancer and key biomarker testing often used in patients with colorectal cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker for all patients. Presenters: Ann Marie Siney, RN, MSN, ANP-BC Division of Hematology/Oncology UCLA Health Santa Monica, California Kathleen Boyle, DScPAS, PA-C Gastrointestinal Cancer Center Dana-Farber Cancer Institute Boston, Massachusetts Link to full program: https://bit.ly/4spkxiC Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to this audio podcast covering biomarker testing in patients with prostate cancer. Learn from Sara Traverso, MMS, PA-C, and Brenda Martone, MSN, ANP-BC, AOCNP, about when to conduct germline and somatic genetic testing in patients with prostate cancer, discussing testing with patients and their caregivers, recognizing actionable biomarkers, and improving APP confidence in the application of biomarker testing results to practice. Presenters: Sara Traverso, MMS, PA-C Physician Assistant Northwestern Medicine Robert H. Lurie Comprehensive Cancer Center Genitourinary Oncology Chicago, Illinois Brenda Martone, MSN, ANP-BC, AOCNP Nurse Practitioner Northwestern Medicine Chicago, Illinois Link to full program: https://bit.ly/3PB4ZJR Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Sam S. Chang, MD, MBA, and Matthew D. Galsky, MD, discuss the rapidly evolving treatment landscape in bladder cancer, highlighting new therapeutic options, emerging clinical trial data, including the latest results presented at ASCO GU 2026, and the growing role of biomarkers and multidisciplinary care, including: New treatment options for BCG-unresponsive non–muscle-invasive bladder cancer Intravesical therapies such as nadofaragene and N-803 The role of ctDNA in measurable residual disease detection Presenters: Sam S. Chang, MD, MBA Patricia and Rodes Hart Chair of Urologic Surgery Chief Surgical Officer Vanderbilt Ingram Cancer Center Nashville, Tennessee Matthew D. Galsky, MD Lillian and Howard Stratton Professor of Medicine Icahn School of Medicine at Mount Sinai Director, Genitourinary Medical Oncology Co-Leader, Cancer Clinical Investigation Program Associate Director for Translational Research Tisch Cancer Institute New York, New York Link to full program: https://bit.ly/479RgQn Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making. Presenters: Rodney Hunter, PharmD, BCOP Director of Clinical Services Memorial Hermann Texas Medical Center Clinical Pharmacy Specialist University of Texas Health Memorial Hermann Cancer Center Professor Texas Southern University College of Pharmacy and Health Sciences Clinical Adjunct Professor McGovern Medical School Houston, Texas Julia L. Ziegengeist, PharmD, BCOP Clinical Pharmacist Specialist, Breast Medical Oncology Levine Cancer, Atrium Health Charlotte, North Carolina Link to full program:https://bit.ly/46SPGlU Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including: How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe Practical sequencing decisions after disease progression Emerging BTK degradersas a promising option for heavily pretreated patients Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Matthew S. Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Leader, Lymphoma Program Dana-Farber/Harvard Cancer Center Director of Clinical Research, Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Nelson Hamerschlak, MD, PhD Head of the Department of Hematology, BMT and Clinical Cell Therapy Einstein Hospital Israelita Sao Paulo, Brazil Stephen Stilgenbauer, MD Medical Director, Comprehensive Cancer Center Ulm (CCCU) Head, Early Clinical Trials Unit (ECTU) Head, Division of CLL Department of Internal Medicine III Comprehensive Cancer Center Ulm (CCCU) University of Medical Center Ulm Ulm, Germany Link to the full program: https://bit.ly/4rsZlqF Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to learn from Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc, about new clinical trial data and updates informing the care of patients with early breast cancer and locally advanced/metastatic breast cancer that were presented at the 2025 San Antonio Breast Cancer Symposium. Presenters: Sara M. Tolaney, MD, MPH Chief, Division of Breast Oncology Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Virginia Kaklamani, MD, DSc Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment A.B. Alexander Distinguished Chair in Oncology Leader, Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center San Antonio, Texas Link to full program:https://bit.ly/46Qv9OK Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including: Clinical outcomes and limitations of first-generation KRAS G12C inhibitors Key unmet needs, including primary and acquired resistance Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy Presenters: Luis Paz-Ares, MD, PhD Head of Medical Oncology Department Hospital Universitario 12 de Octubre Associate Professor, Universidad Complutense de Madrid Madrid, Spain Christine Bestvina, MD Associate Professor University of Chicago Medicine Division of Medicine Section of Hematology/Oncology University of Chicago Medicine Chicago, IllinoisLink to full program:https://bit.ly/4rhoUuN Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including: CD19-directed CAR T-cell therapies Next-generation CD19 bispecific antibodies The evolving role of allogeneic transplant Presenters: Ibrahim Aldoss, MD Associate Professor Division of Leukemia Department of Hematology/HCT City of Hope National Medical Center Duarte, California Bijal Shah, MD, MS Senior Member, Department of Malignant Hematology Moffitt Cancer Center Tampa, Florida Link to full program: https://bit.ly/4cRjiUi Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, discuss novel RAS-targeted therapies for pancreatic cancer, including the following: Optimal KRAS mutation testing Emerging multiselective RAS inhibitors Combination strategies Presenters: Nilofer Azad, MD, FASCO Professor of Oncology Associate Director of Clinical Research Sidney Kimmel Cancer Center at Johns Hopkins University Co-Leader, Developmental Therapeutics Clinical Trials Group Baltimore, Maryland Zev A. Wainberg, MD Professor of Medicine and Surgery Co-Director, GI Oncology Program UCLA School of Medicine Los Angeles, California Content based on an online CME program supported by an educational grant from Revolution Medicines, Inc. Link to full program: https://bit.ly/4avdRZK Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.